Literature DB >> 11682563

In vitro activity of posaconazole against clinical isolates of dermatophytes.

F Barchiesi1, D Arzeni, V Camiletti, O Simonetti, A Cellini, A M Offidani, G Scalise.   

Abstract

A broth macrodilution method following the recommendations established by the National Committee for Clinical Laboratory Standards was used to compare the in vitro activity of posaconazole (PCZ) with that of itraconazole (ITC) against 30 clinical isolates of dermatophytes belonging to six different species. In terms of MICs, PCZ showed an activity equal to that of ITC. MICs of PCZ at which 50% (MIC(50)) and 90% (MIC(90)) of the isolates were inhibited were 0.5 and > 4.0 microg/ml, respectively. The MIC(50) and MIC(90) of ITC were 1.0 and > 4.0 microg/ml, respectively. However, PCZ showed a more potent fungicidal activity than that of ITC against isolates belonging to the genus Microsporum (P = 0.03). PCZ merits further investigation as a potentially useful agent for treatment of dermatophytosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11682563      PMCID: PMC88520          DOI: 10.1128/JCM.39.11.4208-4209.2001

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  9 in total

1.  Fluorometric assessment of In vitro antidermatophytic activities of antimycotics based on their keratin-penetrating power.

Authors:  C N Okeke; R Tsuboi; M Kawai; H Ogawa
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

2.  Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi.

Authors:  A Espinel-Ingroff; M Bartlett; R Bowden; N X Chin; C Cooper; A Fothergill; M R McGinnis; P Menezes; S A Messer; P W Nelson; F C Odds; L Pasarell; J Peter; M A Pfaller; J H Rex; M G Rinaldi; G S Shankland; T J Walsh; I Weitzman
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

3.  Antifungal susceptibility testing of dermatophytes: establishing a medium for inducing conidial growth and evaluation of susceptibility of clinical isolates.

Authors:  C J Jessup; J Warner; N Isham; I Hasan; M A Ghannoum
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

4.  Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus.

Authors:  K L Oakley; G Morrissey; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

5.  Results of German multicenter study of antimicrobial susceptibilities of Trichophyton rubrum and Trichophyton mentagrophytes strains causing tinea unguium. German Collaborative Dermatophyte Drug Susceptibility Study Group.

Authors:  H C Korting; M Ollert; D Abeck
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

6.  Comparison of in vitro activities of voriconazole and five established antifungal agents against different species of dermatophytes using a broth macrodilution method.

Authors:  S Perea; A W Fothergill; D A Sutton; M G Rinaldi
Journal:  J Clin Microbiol       Date:  2001-01       Impact factor: 5.948

7.  Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae.

Authors:  M A Pfaller; S Messer; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

8.  In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens.

Authors:  F Barchiesi; D Arzeni; A W Fothergill; L F Di Francesco; F Caselli; M G Rinaldi; G Scalise
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

Review 9.  The dermatophytes.

Authors:  I Weitzman; R C Summerbell
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

  9 in total
  11 in total

1.  Collaborative evaluation of optimal antifungal susceptibility testing conditions for dermatophytes.

Authors:  Belkys Fernández-Torres; Francisco J Cabañes; Alfonso J Carrillo-Muñoz; Alexandre Esteban; Isabel Inza; Lourdes Abarca; Josep Guarro
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

2.  Comparison of in vitro activities of 17 antifungal drugs against a panel of 20 dermatophytes by using a microdilution assay.

Authors:  Bertrand Favre; Bettina Hofbauer; Kwang-Soo Hildering; Neil S Ryder
Journal:  J Clin Microbiol       Date:  2003-10       Impact factor: 5.948

3.  [New apects in the diagnosis and therapy of dermatomycoses].

Authors:  J Brasch
Journal:  Hautarzt       Date:  2012-05       Impact factor: 0.751

4.  Evaluation of broth microdilution antifungal susceptibility testing conditions for Trichophyton rubrum.

Authors:  D A Santos; J S Hamdan
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

Review 5.  Pharmacokinetic/pharmacodynamic profile of posaconazole.

Authors:  Yanjun Li; Ursula Theuretzbacher; Cornelius J Clancy; M Hong Nguyen; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

6.  Skin concentrations and pharmacokinetics of posaconazole after oral administration.

Authors:  Gopal Krishna; Eric Beresford; Lei Ma; Donna Vickery; Monika Martinho; Xin Yu; Steven Komjathy; Amir Tavakkol
Journal:  Antimicrob Agents Chemother       Date:  2010-03-01       Impact factor: 5.191

Review 7.  Newer systemic antifungal agents : pharmacokinetics, safety and efficacy.

Authors:  Helen W Boucher; Andreas H Groll; Christine C Chiou; Thomas J Walsh
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Posaconazole: A new agent for the prevention and management of severe, refractory or invasive fungal infections.

Authors:  Andrea V Page; W Conrad Liles
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-07       Impact factor: 2.471

Review 9.  Posaconazole: An Update of Its Clinical Use.

Authors:  Simon Leung; Mara N Poulakos; Jade Machin
Journal:  Pharmacy (Basel)       Date:  2015-10-21

Review 10.  Conazoles.

Authors:  Jan Heeres; Lieven Meerpoel; Paul Lewi
Journal:  Molecules       Date:  2010-06-09       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.